Sarah Makowicki sits in the Connecticut State Capitol in Hartford, Conn., on Thursday, March 27, 2025. (AP Photo/Susan Haigh)
States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to get out from under the budgetary squeeze that took them by surprise.